Overview
- The New England Journal of Medicine’s NEJM AI published a retrospective study on Thursday reporting that OpenAI’s o3 model helped generate evidence‑linked leads that contributed to 18 confirmed diagnoses from 376 previously unsolved pediatric genomes.
- Researchers used the model as an assistive reanalysis tool that highlighted candidate gene–disease links while clinicians reviewed results and certified clinical laboratories performed final confirmation.
- The study yielded about a 4.8% additional diagnostic rate but was limited by its retrospective design and did not measure whether the tool saves time, cuts costs, or improves patient outcomes.
- Patients described real personal benefits, including one person who received an ultra‑rare myofibrillar myopathy diagnosis after decades without an answer, showing how diagnoses can change care and provide closure.
- Authors and outside experts stressed strict privacy safeguards and human oversight are required and said the next step is larger, forward‑looking multicenter trials to test real‑time clinical utility and safety.